The Economics of Capacity

‍

In my previous article, I argued that time is a strategic asset and that acceleration creates value. But viewing time solely through the lens of acceleration tells only half the story.

The Economics of Time has two further dimensions. The first is the cost of delay. Every unnecessary delay pushes decisions, milestones, submissions, and product launches further into the future, destroying value along the way.

The second is the value of capacity. Every hour consumed by low-value activities or “busy work” as it is sometimes called, is an hour that cannot be invested in pursuing new opportunities, advancing additional programmes, or generating future revenue.

‍

These two forces are inseparable:

Delay destroys capacity.  Capacity creates opportunity.

Every day lost has a double cost:

….. it delays the value that you expected to create today

….. it consumes the capacity needed to create value tomorrow

‍

‍This is why some of the most valuable AI initiatives are not those that simply automate work, but ones that simultaneously reduce delay and unlock capacity.

To understand why, we need to look at where time is really being lost.

‍

The Hidden Cost of Delay

Most organisations assume that development timelines are determined primarily by major events: patient recruitment; analysis of results; submission; regulatory review; market access.

These milestones are undoubtedly important, but some of the most expensive delays occur elsewhere:

….. teams waiting for information

….. documents moving between functions

….. governance processes taking their course

‍

Individually, these delays may appear insignificant…..a few days here, a week there, a review cycle repeated, a clarification requested.  However, collectively they can add up to months.

The challenge is that these delays rarely appear on project plans. They are hidden within processes, inboxes, meetings, across organisational boundaries, which means they often escape scrutiny.

‍

Let’s consider a late-stage development programme targeting regulatory submission by the end of the year:

….. a protocol amendment adds two weeks

….. data reconciliation takes an additional week

….. document reviews require two further cycles

….. governance approvals are deferred until the next meeting

‍

None of these delays appears significant in isolation, but collectively they may consume six to eight weeks.

The consequence is not simply additional effort:

….. a delayed submission may push regulatory review into a later cycle

….. a delayed approval may defer market access activities

….. a delayed launch may postpone revenue generation and patient access

‍

The challenge is that these costs rarely appear on a project budget. They appear as lost time, and in drug development lost time carries a far greater economic impact than the cost of the work itself.

‍

The Hidden Value of Capacity

Delay does more than destroy value. It also consumes something equally precious, capacity.

When organisations evaluate AI investments, they often focus on labour savings. This can lead us to view capacity primarily as a cost-saving opportunity.  What if the real opportunity lies elsewhere?

‍

In drug development, organisations are rarely constrained by ideas. More often, they are constrained by capacity:

….. additional indications remain unexplored

….. promising programmes are sequenced rather than run in parallel

….. evidence generation is delayed while teams focus on higher-priority activities

Strategic opportunities wait for skilled resources to become available.  Every organisation has opportunities it would like to pursue but cannot currently support.

‍

Let’s consider a company with a marketed product that has the potential for a second indication worth an additional $100–200 million in annual revenue. The opportunity is attractive, the science is promising, and yet progression is delayed because clinical, statistical, and regulatory teams are already operating at full capacity. If AI enables these teams to initiate the programme six months earlier, the value created may be measured not in hours saved, but in millions of dollars of future revenue brought forward.

Or consider a regulatory affairs organisation capable of supporting ten major submissions each year. If AI creates sufficient capacity to support an eleventh submission without increasing headcount, the value is not the salary cost saved, it lies in accelerating an additional asset towards approval and commercialisation.

‍

AI is not simply reducing effort; it is increasing organisational throughput:

….. more opportunities pursued

….. more assets advanced

….. more value created

‍

The Economics of Capacity

This is why the most valuable AI initiatives may not be those that eliminate the greatest number of tasks, but the ones that create the greatest amount of capacity. Because capacity creates strategic options, and strategic options create value.

A team that is 20% more productive is interesting. A team that can pursue an additional indication, accelerate a critical submission, or advance another development programme is transformational.

When organisations remove delay, they do more than accelerate existing work. They create the ability to pursue opportunities that previously remained out of reach.

‍

The fact is that every unnecessary delay has two unintended consequences:

….. it delays the value you expected to create

….. and it consumes capacity that could have been used to create something else

Said another way, the hidden cost of delay is not just the value that is lost today, it is an opportunity that cannot be pursued tomorrow.

The Economics of Capacity framework asks the important question:

….."What could we achieve if capacity were no longer the constraint?"

‍

The future winners in AI may not be the organisations that automate the most work, but those that compress time most effectively, and unlock the most opportunity. 

‍

At Verisian, we are committed to helping companies lower the cost of lost opportunity and achieve maximum value from the pipeline.

If the economics of capacity is on your agenda, I’d enjoy the conversation.

‍‍

About the Author

Carol Collins has over 30 years leadership experience in the global Life Sciences and Healthcare industry, with 20 years in clinical development. Throughout her career she has had a key focus on innovation and transformation to accelerate outcomes, create value  and bring life-saving medicines to patients. She is a strategic advisor to Verisian.

‍

‍

‍